Mangoceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $9.6M
- Price
- $0.4437
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.40%
- Volume
- 646.1K
About
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Quick stats
Shares outstanding21.6M
Computed float15.4M
Float / shares71.2%
Key info
SectorHealthcare
IndustryMedical - Healthcare Information Services
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001938046
AI Summary
AI-generated1/21
minorbullishoffering
Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche
Mangoceuticals secured a $2.5 million strategic investment directly into its subsidiary MangoRx IP Holdings, with an initial $1.75 million tranche already received.
Investors purchase an aggregate 25% membership interest in two tranches, and no MGRX common stock, warrants, or parent securities are being issued, leaving the public capitalization untouched.
The capital funds commercialization of the MGX-0024 antiviral patent portfolio (U.S. Patent No. 11,517,523 plus foreign filings), targeting oral care, livestock feed additive, and poultry applications. The second $750,000 tranche is due by November 28, 2026, subject to conditions.
Red flags
- Company cedes 25% of the subsidiary holding its core antiviral patent portfolio
- Second $750,000 tranche is conditional and subject to subscription agreement terms
- Disclosed current non-compliance with certain Nasdaq listing standards relating to stock price
- Extensive outstanding warrants and convertible securities creating dilution overhang per forward-looking statements